Freitag Julien, Bates Dan, Boyd Richard, Shah Kiran, Barnard Adele, Huguenin Leesa, Tenen Abi
Melbourne Stem Cell Centre, Level 2, 116-118 Thames St, Box Hill North, VIC, 3128, Australia.
Monash University, Melbourne, Australia.
BMC Musculoskelet Disord. 2016 May 26;17:230. doi: 10.1186/s12891-016-1085-9.
Osteoarthritis is a leading cause of pain and disability across the world. With an aging population its prevalence is likely to further increase. Current accepted medical treatment strategies are aimed at symptom control rather than disease modification. Surgical options including joint replacement are not without possible significant complications. A growing interest in the area of regenerative medicine, led by an improved understanding of the role of mesenchymal stem cells in tissue homeostasis and repair, has seen recent focused efforts to explore the potential of stem cell therapies in the active management of symptomatic osteoarthritis. Encouragingly, results of pre-clinical and clinical trials have provided initial evidence of efficacy and indicated safety in the therapeutic use of mesenchymal stem cell therapies for the treatment of knee osteoarthritis. This paper explores the pathogenesis of osteoarthritis and how mesenchymal stem cells may play a role in future management strategies of this disabling condition.
骨关节炎是全球疼痛和残疾的主要原因。随着人口老龄化,其患病率可能会进一步上升。目前公认的医学治疗策略旨在控制症状而非改变病情。包括关节置换在内的手术选择并非没有可能出现的重大并发症。在对间充质干细胞在组织稳态和修复中的作用有了更深入了解的引领下,再生医学领域的关注度日益提高,近期人们集中精力探索干细胞疗法在有症状的骨关节炎积极管理中的潜力。令人鼓舞的是,临床前和临床试验结果已提供了疗效的初步证据,并表明间充质干细胞疗法用于治疗膝骨关节炎具有安全性。本文探讨了骨关节炎的发病机制以及间充质干细胞在这种致残性疾病未来管理策略中可能发挥的作用。